Related Experiment Videos
Congestive heart failure from left ventricular diastolic dysfunction in systemic hypertension
M Iriarte1, N Murga, D Sagastagoitia
1University of the Basque Country, Institute of Cardiology, Hospital Civil de Basurto, Bilbao (Bizkaia), Spain.
The American Journal of Cardiology
|February 1, 1993
Summary
Congestive heart failure with normal ejection fraction in hypertensive patients presents two distinct profiles: one with severe hypertrophy and another with significant myocardial ischemia. Treatment should target the specific underlying cause for better outcomes.
Area of Science:
- Cardiology
- Internal Medicine
- Hypertension Research
Background:
- Congestive heart failure (CHF) with preserved ejection fraction (HFpEF) was previously considered clinically uniform.
- Distinguishing HFpEF profiles is crucial for targeted therapeutic strategies.
Purpose of the Study:
- To investigate distinct clinical and pathophysiological profiles within hypertensive patients experiencing CHF with normal ejection fraction.
- To identify subgroups within HFpEF based on echocardiographic hypertrophy and myocardial ischemia.
Main Methods:
- Studied 36 hypertensive patients with recent CHF and normal ejection fraction (> or = 50%).
- Divided patients into two groups based on ventricular mass/volume ratio (Group A: >1.8, Group B: <1.8).
- Utilized echocardiography, thallium-201 scintigraphy, and clinical assessments (auscultation, cardiothoracic ratio).
Main Results:
- Group A (high hypertrophy) showed higher ejection fraction, smaller ventricular diameters, and lower thallium-201 positivity (indicating less ischemia).
- Group B (less hypertrophy) had a higher rate of myocardial ischemia, evidenced by thallium-201 uptake and coronary stenosis.
- Clinical findings differentiated groups: Group A had more S4 sounds and smaller cardiothoracic ratios; Group B had more S3 sounds.
Conclusions:
- Hypertensive CHF with normal ejection fraction manifests as two distinct phenotypes: one dominated by severe left ventricular hypertrophy and the other by significant myocardial ischemia.
- Therapeutic approaches should be tailored: regression of hypertrophy for the first profile and improvement of ischemia for the second.